Diagnostic Value of Rheumatoid Factor and Anti-CCP in Seropositive and Seronegative Rheumatoid arthritis patients at a Tertiary Hospital in Tamil Nadu
Keywords:
Rheumatoid Arthritis, anti-cyclic citrullinated peptide, Rheumatoid Factor, IgG ELISA, Autoimmune diseaseAbstract
Rheumatoid Arthritis (RA) is not an uncommon disease and its rate of prevalence is estimated about 1- 1.5% across the globe. It is a non-organ specific autoimmune disease which is categorized by systemic, chronic and symmetric inflammation involving multiple joints, predominantly the small joints. The aim of this study is to evaluate the diagnostic value of Anti-CCP autoantibodies with the standard rheumatoid factor (RF) among seropositive and negative patients attending a tertiary care hospital. This is a cross sectional study was conducted in a tertiary care hospital in and around Coimbatore district. The total study population was categorized into two groups 80 RF positive and 80 RF negative for the performance of anti-CCP ELISA. The age of the RA positive patients ranges from 28 to 83 years and for negative patients about 18 to 75 years old. Among the RA-positive group, 19 patients (23.7%) were tested positive for anti-CCP antibodies, while the remaining 61 (76.3%) were negative. In the RA-negative group, 15 patients (18.7%) were anti-CCP positive, whereas 65 (81.3%) tested negative. Rheumatoid factor is the significant diagnostic marker for RA till the discovery of Anti –CCP autoantibodies. The study concludes that anticitrullinated protein antibodies are more sensitive than RF antibodies. Anti-CCP is considered to be early diagnostic marker for the diagnosis of RA than other serological tests.
Downloads
Metrics
References
Sharma, P.K., Hota D, Pandhi P. Biologics in rheumatoid arthritis. J. Assoc. Physicians India. 2001;52: 231-236.
John, S, Worthington J. Genetic epidemiology. Approaches to the genetic analysis of rheumatoid arthritis. Arthritis Res. 2001;3(4):216-220.
Alessandri C, Priori R, Modesti M, Mancini R, Valesini G. The role of anti-cyclic cytrullinate antibodies testing in rheumatoid arthritis. Clinic Rev Allerg Immunol 2008;34:45-9.
Ogrendik, M. Oral Bacteria Are Responsible for the Etiology of Rheumatoid Arthritis. Open Journal of Rheumatology and Autoimmune Diseases, 2014;4:162-169. doi: 10.4236/ojra.2014.43023.
De Rycke L, Peene I, Hoffman IE, et al. Rheumatoid factor and anti-citrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestation. Ann Rheum Dis 2004;63:1587-93.
Bas S, Perneger TV, Seitz M, Tiercy MJ, Lombard RP, Guerne AP. Diagnostic tests for rheumatoid arthritis. Comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factor. Rheumatol 2002;41:809-14.
Zendman WJ, Venrooij VJW, Pruijin MJ. Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatol 2006;45:20-5.
Miriovsky BJ, Michaud K, Thiele GM, O’Dell JR, Cannon GW, et al. Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Ann Rheum Dis. 2010; 69:1292-1297.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and rheumatism. 2010; 62:2569-2581.
Hayashi N, Kumagai S. Anti-cyclic citrullinated peptide antibodies and rheumatoid arthritis. Rinsho Byori. 2010;58:466-479.
Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis. 2003;62:870-874.
Chou RC, Kane M, Ghimire S, Gautam S, Gui J. Treatment for Rheumatoid Arthritis and Risk of Alzheimer's Disease: A Nested Case-Control Analysis. CNS Drugs. 2016 Nov;30(11):1111-1120.
Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP anti-body test predicts the disease course during three years in early rheumatoidarthritis.Ann Rheum Dis 2004;63:1085-9.
Nadeem Afzal, Sara Karim, Fazzul-E-Haque Mahmud, Waqas Sami, Maria Arif, Sarwar Abbas.Evaluation of Anti-CCP Antibody for Diagnosis of Rheumatoid Arthritis. Clin. Lab. 2011;57:895-899.
Vencovsky J, et al Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis. 2003;62:427–30.
Kroot EJ, de Jong BA, van Leeuwen MA et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent onset rheumatoid arthritis. Arthritis Rheum. 2000;43:1831–5.
Mediwake R, Isenberg DA, Schellekens GA, van Venrooij WJ. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis; 2001;60:67–8.
Burska AN, Hunt L, Boissinot M, Strollo R, Ryan BJ, Vital E, et al. Autoantibodies to posttranslational modifications in rheumatoid arthritis. Mediators Inflamm. 2014;2014:492873. doi:10.1155/2014/492873.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
